Contribution of the PI3K/MMPs/Ln-5γ2 and EphA2/FAK/Paxillin signaling pathways to tumor growth and vasculogenic mimicry of gallbladder carcinomas

Lu,Xin-Sui; Sun,Wei; Ge,Chun-Yan; Zhang,Wen-Zhong; Fan,Yue-Zu

doi:10.3892/ijo.2013.1897

Contribution of the PI3K/MMPs/Ln-5γ2 and EphA2/FAK/Paxillin signaling pathways to tumor growth and vasculogenic mimicry of gallbladder carcinomas

Authors:
- Xin-Sui Lu
- Wei Sun
- Chun-Yan Ge
- Wen-Zhong Zhang
- Yue-Zu Fan
View Affiliations

Affiliations: Department of Surgery, Tongji Hospital, Tongji University School of Medicine, Shanghai, P.R. China, Department of Surgery, Shanghai Tenth People's Hospital, Tongji University, Shanghai, P.R. China
Published online on: April 15, 2013 https://doi.org/10.3892/ijo.2013.1897
Pages: 2103-2115

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Vasculogenic mimicry (VM) is a new tumor blood supply in some highly aggressive malignant tumors. We previously reported VM in human gallbladder carcinomas, 3-D matrices in vitro and nude mouse xenografts in vivo of highly aggressive GBC-SD cells and its clinical significance. In this study, we further studied the underlying mechanisms of VM in gallbladder carcinomas via the 3-D matrix in vitro, the nude mouse xenografts in vivo of GBC-SD or SGC-996 cells, immunohistochemistry (H&E staining and CD31-PAS double staining), electron microscopy, expression of MMP-2, MT1-MMP, PI3K, Ln-5γ2, EphA2, FAK and Paxillin-P proteins/mRNAs determined by SABC, ELISA, immunofluorescence, western blotting and qRT-PCR, respectively. It was shown that all of untreated highly aggressive GBC-SD cells and xenografts formed vasculogenic-like structures within 2 weeks of seeding and injecting, and facilitated the growth of tumor cells or xenografts; whereas poorly aggressive SGC-996 cells or GBC-SD cells treated by TIMP-2 were unable to form the vasculogenic-like structures with the same conditions; and tumor xenograft growth was inhibited. Expression of MMP-2, MT1-MMP proteins/mRNAs from sections and supernates of 3-D matrix in vitro, expression of PI3K, MMP-2, MT1-MMP, Ln-5γ2, EphA2, FAK and Paxillin-P proteins/mRNAs from sections of xenografts in vivo in untreated GBC-SD group was upregulated significantly (all P<0.001); however, expression of these VM signal-related proteins/mRNAs in the SGC-996 group and GBC-SD treated by the TIMP-2 group was significantly downregulated (all P<0.001). Thus, we identified for the first time that highly aggressive GBC-SD cells formed VM in vitro and in vivo through the upregulation of PI3K/MMPs/Ln-5γ2 and/or EphA2/FAK/Paxillin signaling. PI3K/MMPs/Ln-5γ2 and EphA2/FAK/Paxillin as key signaling pathways in a coordinated manner contributed to tumor growth and VM of gallbladder carcinomas and provided novel targets that could be potentially exploited for therapeutic intervention of human gallbladder carcinomas.

View Figures

View References

1	Gourgiotis S, Kocher HM, Solaini L, Yarollahi A, Tsiambas E and Salemis NS: Gallbladder cancer. Am J Surg. 196:252–264. 2008. View Article : Google Scholar
2	Lazcano-Ponce EC, Miquel JF, Muñoz N, Herrero R, Ferrecio C, Wistuba II, Alonso de Ruiz P, Aristi Urista G and Nervi F: Epidemiology and molecular pathology of gallbladder cancer. CA Cancer J Clin. 51:349–364. 2001. View Article : Google Scholar : PubMed/NCBI
3	Reddy SK and Clary BM: Surgical management of gallbladder cancer. Surg Oncol Clin North Am. 18:307–324. 2009. View Article : Google Scholar : PubMed/NCBI
4	Li LD, Zhang SW, Lu FZ, Mu R, Sun XD and Huangpu XM: Research on characteristics of mortality spectrum and type composition of malignant tumors in China. Zhonghua Zhongliu Zazhi. 19:323–328. 1997.PubMed/NCBI
5	Hsing AW, Gao YT, Devesa SS, Jin F and Fraumeni JF Jr: Rising incidence of biliary tract cancers in Shanghai, China. Int J Cancer. 75:368–370. 1998. View Article : Google Scholar : PubMed/NCBI
6	Chakravarty KD, Yeh CN, Jan YY and Chen MF: Factors influencing long-term survival in patients with T3 gallbladder adenocarcinoma. Digestion. 79:151–157. 2009. View Article : Google Scholar : PubMed/NCBI
7	Konstantinidis IT, Deshpande V, Genevay M, Berger D, Fernandez-del Castillo C, Tanabe KK, Zheng H, Lauwers GY and Ferrone CR: Trends in presentation and survival for gallbladder cancer during a period of more than 4 decades: a single-institution experience. Arch Surg. 144:441–447. 2009. View Article : Google Scholar : PubMed/NCBI
8	Ishii H, Furuse J, Yonemoto N, Nagase M, Yoshino M and Sato T: Chemotherapy in the treatment of advanced gallbladder cancer. Oncology. 66:138–142. 2004. View Article : Google Scholar : PubMed/NCBI
9	Morise Z, Sugioka A, Tanahashi Y, Okabe Y, Ikeda M, Kagawa T and Takeura C: Treatment of patients with unresectable advanced carcinoma of biliary tract chemotherapy and surgical resection. Anticancer Res. 29:1783–1786. 2009.PubMed/NCBI
10	Mahantshetty UM, Palled SR, Engineer R, Homkar G, Shrivastava SK and Shukla PJ: Adjuvant radiation therapy in gallbladder cancers: 10 years experience at Tata Memorial Hospital. J Cancer Res Ther. 2:52–56. 2006.PubMed/NCBI
11	Mojica P, Smith D and Ellenhorn J: Adjuvant radiation therapy is associated with improved survival for gallbladder carcinoma with regional metastatic disease. J Surg Oncol. 96:8–13. 2007. View Article : Google Scholar : PubMed/NCBI
12	Shukla PJ and Barreto SG: Gallbladder cancer: we need to do better! Ann Surg Oncol. 16:2084–2085. 2009.
13	Maniotis AJ, Folberg R, Hess A, Seftor EA, Gardner LM, Pe’er J, Trent JM, Meltzer PS and Hendrix MJ: Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol. 155:739–752. 1999. View Article : Google Scholar : PubMed/NCBI
14	Warso MA, Maniotis AJ, Chen X, Majumdar D, Patel MK, Shilkaitis A, Gupta TK and Folberg R: Prognostic significance of periodic acid-Schiff-positive patterns in primary cutaneous melanoma. Clin Cancer Res. 7:473–477. 2001.PubMed/NCBI
15	Shirakawa K, Wakasugi H, Heike Y, Watanabe I, Yamada S, Saito K and Konishi F: Vasculogenic mimicry and pseudo-comedo formation in breast cancer. Int J Cancer. 99:821–828. 2002. View Article : Google Scholar : PubMed/NCBI
16	Sood AK, Fletcher MS, Zahn CM, Gruman LM, Coffin JE, Seftor EA and Hendrix MJ: The clinical significance of tumor cell-lined vasculature in ovarian carcinoma: implications for anti-vasculogenic therapy. Cancer Biol Ther. 1:661–664. 2002. View Article : Google Scholar : PubMed/NCBI
17	Sun B, Zhang S, Zhang D, Du J, Guo H, Zhao X, Zhang W and Hao X: Vasculogenic mimicry is associated with high tumor grade, invasion and metastasis, and short survival in patients with hepatocellular carcinoma. Oncol Rep. 16:693–698. 2006.PubMed/NCBI
18	Guzman G, Cotler SJ, Lin AY, Maniotis AJ and Folberg R: A pilot study of vasculogenic mimicry immunohistochemical expression in hepatocellular carcinoma. Arch Pathol Lab Med. 131:1776–1781. 2007.PubMed/NCBI
19	Li M, Gu Y, Zhang Z, Zhang S, Zhang D, Saleem AF, Zhao X and Sun B: Vasculogenic mimicry: a new prognostic sign of gastric adenocarcinoma. Pathol Oncol Res. 16:259–266. 2010. View Article : Google Scholar : PubMed/NCBI
20	Baeten CI, Hillen F, Pauwels P, de Bruine AP and Baeten CG: Prognostic role of vasculogenic mimicry in colorectal cancer. Dis Colon Rectum. 52:2028–2035. 2009. View Article : Google Scholar : PubMed/NCBI
21	Hess AR, Seftor EA, Seftor RE and Hendrix MJ: Phosphoinositide 3-kinase regulates membrane Type 1-matrix metalloproteinase (MMP) and MMP-2 activity during melanoma cell vasculogenic mimicry. Cancer Res. 63:4757–4762. 2003.PubMed/NCBI
22	Seftor RE, Seftor EA, Koshikawa N, Meltzer PS, Gardner LM, Bilban M, Stetler-Stevenson WG, Quaranta V and Hendrix MJ: Cooperative interactions of laminin 5 gamma 2 chain, matrix metalloproteinase-2, and membrane type-1-matrix/metalloproteinase are required for mimicry of embryonic vasculogenesis by aggressive melanoma. Cancer Res. 61:6322–6327. 2001.
23	Seftor RE, Seftor EA, Kirschmann DA and Hendrix MJ: Targeting the tumor microenvironment with chemically modified tetracyclines: inhibition of laminin 5 gamma2 chain promigratory fragments and vasculogenic mimicry. Mol Cancer Ther. 1:1173–1179. 2002.
24	Sood AK, Fletcher MS, Coffin JE, Yang M, Seftor EA, Gruman LM, Gershenson DM and Hendrix MJ: Functional role of matrix metalloproteinases in ovarian tumor cell plasticity. Am J Obstet Gynecol. 190:899–909. 2004. View Article : Google Scholar : PubMed/NCBI
25	Hess AR, Seftor EA, Gardner LM, Carles-Kinch K, Schneider GB, Seftor RE, Kinch MS and Hendrix MJ: Molecular regulation of tumor cell vasculogenic mimicry by tyrosine phosphorylation: role of epithelial cell kinase (Eck/EphA2). Cancer Res. 61:3250–3255. 2001.PubMed/NCBI
26	Margaryan NV, Strizzi L, Abbott DE, Seftor EA, Rao MS, Hendrix MJ and Hess AR: EphA2 as a promoter of melanoma tumorigenicity. Cancer Biol Ther. 8:279–288. 2009. View Article : Google Scholar : PubMed/NCBI
27	Hess AR, Margaryan NV, Seftor EA and Hendrix MJ: Deciphering the signaling events that promote melanoma tumor cell vasculogenic mimicry and their link to embryonic vasculogenesis: role of the Eph receptors. Dev Dyn. 236:3283–3296. 2007. View Article : Google Scholar : PubMed/NCBI
28	Hess AR and Hendrix MJ: Focal adhesion kinase signaling and the aggressive melanoma phenotype. Cell Cycle. 5:478–480. 2006. View Article : Google Scholar : PubMed/NCBI
29	Hess AR, Postovit LM, Margaryan NV, Seftor EA, Schneider GB, Seftor RE, Nickoloff BJ and Hendrix MJ: Focal adhesion kinase promotes the aggressive melanoma phenotype. Cancer Res. 65:9851–9860. 2005. View Article : Google Scholar : PubMed/NCBI
30	Ruf W, Seftor EA, Petrovan RJ, Weiss RM, Gruman LM, Margaryan NV, Seftor RE, Miyagi Y and Hendrix MJ: Differential role of tissue factor pathway inhibitors 1 and 2 in melanoma vasculogenic mimicry. Cancer Res. 63:5381–5389. 2003.PubMed/NCBI
31	Wang JY, Sun T, Zhao XL, Zhang SW, Zhang DF, Gu Q, Wang XH, Zhao N, Qie S and Sun BC: Functional significance of VEGF-a in human ovarian carcinoma: role in vasculogenic mimicry. Cancer Biol Ther. 7:758–766. 2008. View Article : Google Scholar : PubMed/NCBI
32	Ge CY and Fan YZ: Vasculogenic mimicry and its molecules signaling pathways. Chin Med Abstr (Surg). 15:344–350. 2006.
33	Fan YZ and Sun W: Molecular regulation of vasculogenic mimicry in tumors and potential tumor-target therapy. World J Gastrointest Surg. 2:117–127. 2010. View Article : Google Scholar : PubMed/NCBI
34	Fan YZ, Sun W, Zhang WZ and Ge CY: Vasculogenic mimicry in human primary gallbladder carcinoma and clinical significance thereof. Zhonghua Yi Xue Za Zhi. 87:145–149. 2007.PubMed/NCBI
35	Sun W, Shen ZY, Zhang H, Fan YZ, Zhang WZ, Zhang JT, Lu XS and Ye C: Overexpression of HIF-1α in primary gall-bladder carcinoma and its relation to vasculogenic mimicry and unfavourable prognosis. Oncol Rep. 27:1990–2002. 2012.
36	Sun W, Fan YZ, Zhang WZ and Ge CY: A pilot histomorphology and hemodynamic of vasculogenic mimicry in gallbladder carcinomas in vivo and in vitro. J Exp Clin Cancer Res. 30:462011. View Article : Google Scholar : PubMed/NCBI
37	Link W, Rosado A, Fominaya J, Thomas JE and Carnero A: Membrane localization of all class I PI3-kinase isoforms suppresses c-Myc-induced apoptosis in Rat1 fibroblasts via Akt. J Cell Biochem. 95:979–989. 2005. View Article : Google Scholar : PubMed/NCBI
38	McCawley LJ and Matrisian LM: Matrix metalloproteinases: multifunctional contributors to tumor progression. Mol Med Today. 6:149–156. 2000. View Article : Google Scholar : PubMed/NCBI
39	Noel A, Gilles C, Bajou K, Devy L, Kebers F, Lewalle JM, Maquoi E, Munaut C, Remacle A and Foidart JM: Emerging roles for proteinases in cancer. Invasion Metastasis. 17:221–239. 1997.PubMed/NCBI
40	Stetler-Stevenson WG: Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention. J Clin Invest. 103:1237–1241. 1999. View Article : Google Scholar : PubMed/NCBI
41	Seiki M: Membrane-type matrix metalloproteinases. APMIS. 107:137–143. 1999. View Article : Google Scholar
42	Chang C and Werb Z: The many faces of metalloproteases: cell growth, invasion, angiogenesis and metastasis. Trends Cell Biol. 11:S37–S43. 2001. View Article : Google Scholar : PubMed/NCBI
43	Lafleur MA, Handsley MM, Knauper V, Murphy G and Edwards DR: Endothelial tubulogenesis within fibrin gels specifically requires the activity of membrane-type-matrix metalloproteinases (MT-MMPs). J Cell Sci. 115:3427–3438. 2002.PubMed/NCBI
44	Koike T, Vernon RB, Hamner MA, Sadoun E and Reed MJ: MT1-MMP, but not secreted MMPs, influences the migration of human microvascular endothelial cells in 3-dimensional collagen gels. J Cell Biochem. 86:748–758. 2002. View Article : Google Scholar : PubMed/NCBI
45	Haas TL, Davis SJ and Madri JA: Three-dimensional type I collagen lattices induce coordinate expression of matrix metalloproteinases MT1-MMP and MMP-2 inmicrovascular endothelial cells. J Biol Chem. 273:3604–3610. 1998. View Article : Google Scholar : PubMed/NCBI
46	Hendrix MJ, Seftor EA, Kirschmann DA, Quaranta V and Seftor RE: Remodeling of the microenvironment by aggressive melanoma tumor cells. Ann NY Acad Sci. 995:151–161. 2003. View Article : Google Scholar : PubMed/NCBI
47	Brantley DM, Cheng N, Thompson EJ, Lin Q, Brekken RA, Thorpe PE, Muraoka RS, Cerretti DP, Pozzi A, Jackson D, Lin C and Chen J: Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo. Oncogene. 21:7011–7026. 2002. View Article : Google Scholar : PubMed/NCBI
48	Cheng N, Brantley DM, Liu H, Lin Q, Enriquez M, Gale N, Yancopoulos G, Cerretti DP, Daniel TO and Chen J: Blockade of EphA receptor tyrosine kinase activation inhibits vascular endothelial cell growth factor-induced angiogenesis. Mol Cancer Res. 1:2–11. 2002. View Article : Google Scholar : PubMed/NCBI
49	Miao H, Burnett E, Kinch M, Simon E and Wang B: Activation of EphA2 kinase suppresses integrin function and causes focal-adhesion-kinase dephosphorylation. Nat Cell Biol. 2:62–69. 2000. View Article : Google Scholar : PubMed/NCBI
50	Hendrix MJ, Seftor EA, Meltzer PS, Gardner LM, Hess AR, Kirschmann DA, Schatteman GC and Seftor RE: Expression and functional significance of VE-cadherin in aggressive human melanoma cells: role in vasculogenic mimicry. Proc Natl Acad Sci USA. 98:8018–8023. 2001. View Article : Google Scholar : PubMed/NCBI
51	Hess AR, Seftor EA, Gruman LM, Kinch MS, Seftor RE and Hendrix MJ: VE-cadherin regulates EphA2 in aggressive melanoma cells through a novel signaling pathway: implications for vasculogenic mimicry. Cancer Biol Ther. 5:228–233. 2006. View Article : Google Scholar : PubMed/NCBI
52	Schaller MD: Paxillin: a focal adhesion-associated adaptor protein. Oncogene. 20:6459–6472. 2001. View Article : Google Scholar : PubMed/NCBI
53	Stetler-Stevenson WG, Krutzsch HC and Liotta LA: TIMP-2, a new member of the metalloproteinase inhibitor family. J Biol Chem. 264:17374–17378. 1989.PubMed/NCBI
54	Goldberg GI, Marmer BL, Grant GA, Eisen AZ, Wilhelm S and He C: Human 72-kDa type IV collagenase forms a complex with a tissue inhibitor of metalloproteinase inhibitor. Proc Nati Acad Sci USA. 86:8207–8211. 1989. View Article : Google Scholar : PubMed/NCBI
55	Albini A, Melchiori A, Santi L, Liotta LA, Brown PD and Stetler-Stevenson WG: Tumor cell invasion inhibited by TIMP-2. J Natl Cancer Inst. 83:775–779. 1991. View Article : Google Scholar : PubMed/NCBI
56	Liotta LA and Stetler-Stevenson WG: Tumor invasion and metastasis: an imbalance of positive and negative regulation. Cancer Res. 51(Suppl): S5054–S5059. 1991.PubMed/NCBI